Emixustat
CAS No. 1141777-14-1
Emixustat ( ACU-4429 )
产品货号. M10502 CAS No. 1141777-14-1
Emixustat (ACU-4429) is a first in class small-molecule inhibitor of the visual cycle isomerase (RPE65) with IC50 of 4.4 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
50MG | ¥8068 | 有现货 |
|
100MG | ¥14094 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Emixustat
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Emixustat (ACU-4429) is a first in class small-molecule inhibitor of the visual cycle isomerase (RPE65) with IC50 of 4.4 nM.
-
产品描述Emixustat (ACU-4429) is a first in class small-molecule inhibitor of the visual cycle isomerase (RPE65) with IC50 of 4.4 nM; reduces the production of visual chromophore (11-cis retinal) in wild-type mice following a single oral dose (ED50 = 0.18 mg/kg).Other Indication Phase 3 Clinical
-
同义词ACU-4429
-
通路Others
-
靶点Other Targets
-
受体Other Targets
-
研究领域Other Indications
-
适应症Other Disease
化学信息
-
CAS Number1141777-14-1
-
分子量263.38
-
分子式C16H25NO2
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 43 mg/mL
-
SMILESC1CCC(CC1)COC2=CC=CC(=C2)C(CCN)O
-
化学全称Benzenemethanol, α-(2-aminoethyl)-3-(cyclohexylmethoxy)-, (αR)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kiser PD, et al. Nat Chem Biol. 2015 Jun;11(6):409-15.
2. Bavik C, et al. PLoS One. 2015 May 13;10(5):e0124940.
3. Zhang J, et al. J Clin Invest. 2015 Jul 1;125(7):2781-94.
2. Bavik C, et al. PLoS One. 2015 May 13;10(5):e0124940.
3. Zhang J, et al. J Clin Invest. 2015 Jul 1;125(7):2781-94.
产品手册
关联产品
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.
-
Justicidin A
Justicidin A is a type of bioactive chemical from Justica procumbens.
-
Dehydrojuncusol
Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.